Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background The clinical significance of mitral annular calcification (MAC) in patients undergoing mitral transcatheter edge-to-edge repair is not well understood. There is limited evidence regarding the feasibility, durability of repair, and the prognostic value of MAC in this population. We sought to examine the prognostic value of MAC, its severity, and its impact on procedural success and durability of mitral transcatheter edge-to-edge repair. Methods and Results We reviewed the records of 280 patients with moderate-severe or severe mitral regurgitation who underwent mitral transcatheter edge-to-edge repair with MitraClip from March 2014 to March 2022. The primary end point was cumulative survival at 1 year. Independent factors associated with the primary end point were identified using multivariable Cox regression. Among 280 patients included in the final analysis, 249 had none/mild MAC, and 31 had moderate/severe MAC. Median follow-up was 23.1 months (interquartile range: 11.1-40.4). Procedural success was comparable in the MAC and non-MAC groups (92.6% versus 91.4%, =0.79) with similar rates of residual mitral regurgitation ≤2 at 1 year (86.7% versus 93.2%, =0.55). Moderate/severe MAC was associated with less improvement in New York Heart Association III/IV at 30 days when compared with none/mild MAC (45.8% versus 14.3%, =0.001). The moderate/severe MAC group had lower cumulative 1-year survival (56.8% versus 80.0%, hazard ratio [HR], 1.98 [95% CI, 1.27-3.10], =0.002). Moderate/severe MAC and Society of Thoracic Surgeons predicted risk of mortality for mitral valve repair were independently associated with the primary end point (HR, 2.20 [1.10-4.41], =0.02; and HR, 1.014 [1.006-1.078], =0.02, respectively). Conclusions Mitral TEER is a safe and feasible intervention in selected patients with significant MAC and associated with similar mitral regurgitation reduction at 1 year compared with patients with none/mild MAC. Patients with moderate/severe MAC had a high 1-year mortality and less improvement in their symptoms after TEER.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10727232 | PMC |
| http://dx.doi.org/10.1161/JAHA.123.031118 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Racial Disparity in Myeloablative Hematopoietic Cell Transplantation Outcomes in Patients with Hematological Malignancies Older Than 45 Years.
Blood Cell Ther
August 2025
Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver, Canada.
Introduction: The impact of race on outcomes of allogeneic hematopoietic cell transplants (HCT) has long been a field of research. The Center for International Blood and Marrow Transplant Research (CIBMTR) studies have shown worse survival for Black and Hispanic patients within the first year after HCT, but rates evened out for one-year survivors. From our personal experience, we hypothesize that the outcomes of South Asians (age ≥ 45 years) receiving myeloablative conditioning (MAC) are also worse compared to other races.
View Article and Find Full Text PDFIncreased Amounts of Epicardial Fat Tissue Are Not Associated With Mitral Annular Calcification in Patients With Severe Aortic Stenosis Planned for Transcatheter Aortic Valve Implantation.
Struct Heart
August 2025
Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany.
Background: Mitral annular calcification (MAC) is a common finding in the elderly that is associated with worse outcomes. It is postulated that MAC is a different form of atherosclerosis. Epicardial fat tissue (EFT) is in close contact with different heart structures and is especially pronounced in the atrioventricular grooves and the area surrounding the atrioventricular valve apparatus.
View Article and Find Full Text PDFPrognostic significance of mitral annular calcification assessed by computed tomography for transcatheter edge-to-edge repair outcomes.
EuroIntervention
August 2025
Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, USA.
Background: Mitral annular calcification (MAC) presents challenges for transcatheter edge-to-edge repair (TEER). Limited data exist on how the anatomical features of MAC, assessed by computed tomography (CT), may be associated with TEER outcomes.
Aims: We sought to examine the association between CT features of MAC and clinical outcomes after TEER at 3 years.
CD34+ Cell Dose, Measurable Residual Disease, and Outcome After Myeloablative HLA-Matched Peripheral Blood Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia.
Cancers (Basel)
July 2025
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
: The impact of donor graft cell composition on post-HCT outcomes in AML remains controversial. Furthermore, it is unknown whether this interacts with pre-HCT MRD status. We evaluated the impact of CD34+ and CD3+ cell doses on outcomes of myeloablative conditioning (MAC) HCT in patients with myelodysplastic neoplasm (MDS)/AML or AML with and without detectable MRD in pre-HCT bone marrow specimens.
View Article and Find Full Text PDFTranscatheter edge-to-edge repair in patients with mitral annular calcification: A systematic review and meta-analysis.
Am J Med Sci
July 2025
Department of Cardiology, Jefferson-Einstein Hospital, Philadelphia, PA, USA.
Background: Mitral annular calcification (MAC) is common in patients with functional mitral regurgitation undergoing transcatheter edge-to-edge mitral valve repair (TEER). However, the safety and effectiveness of TEER systems in patients with MAC is poorly understood.
Methods: We systematically reviewed multiple online databases to identify studies that reported outcomes in patients undergoing TEER with underlying moderate/severe MAC versus those with no/mild MAC.